TAK Relative Valuation
TAK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TAK is overvalued; if below, it's undervalued.
Historical Valuation
Takeda Pharmaceutical Co Ltd (TAK) is now in the Fair zone, suggesting that its current forward PE ratio of 22.52 is considered Fairly compared with the five-year average of 27.03. The fair price of Takeda Pharmaceutical Co Ltd (TAK) is between 10.06 to 22.94 according to relative valuation methord.
Relative Value
Fair Zone
10.06-22.94
Current Price：14.07
Fair
22.52
PE
1Y
3Y
5Y
Trailing
Forward
9.45
EV/EBITDA
Takeda Pharmaceutical Co Ltd. (TAK) has a current EV/EBITDA of 9.45. The 5-year average EV/EBITDA is 9.38. The thresholds are as follows: Strongly Undervalued below 7.06, Undervalued between 7.06 and 8.22, Fairly Valued between 10.55 and 8.22, Overvalued between 10.55 and 11.71, and Strongly Overvalued above 11.71. The current Forward EV/EBITDA of 9.45 falls within the Historic Trend Line -Fairly Valued range.
22.62
EV/EBIT
Takeda Pharmaceutical Co Ltd. (TAK) has a current EV/EBIT of 22.62. The 5-year average EV/EBIT is 25.96. The thresholds are as follows: Strongly Undervalued below 9.48, Undervalued between 9.48 and 17.72, Fairly Valued between 34.21 and 17.72, Overvalued between 34.21 and 42.45, and Strongly Overvalued above 42.45. The current Forward EV/EBIT of 22.62 falls within the Historic Trend Line -Fairly Valued range.
2208.25
PS
Takeda Pharmaceutical Co Ltd. (TAK) has a current PS of 2208.25. The 5-year average PS is 26.01. The thresholds are as follows: Strongly Undervalued below -486.51, Undervalued between -486.51 and -230.25, Fairly Valued between 282.27 and -230.25, Overvalued between 282.27 and 538.53, and Strongly Overvalued above 538.53. The current Forward PS of 2208.25 falls within the Strongly Overvalued range.
5.48
P/OCF
Takeda Pharmaceutical Co Ltd. (TAK) has a current P/OCF of 5.48. The 5-year average P/OCF is 6.79. The thresholds are as follows: Strongly Undervalued below 5.61, Undervalued between 5.61 and 6.20, Fairly Valued between 7.39 and 6.20, Overvalued between 7.39 and 7.98, and Strongly Overvalued above 7.98. The current Forward P/OCF of 5.48 falls within the Strongly Undervalued range.
8.24
P/FCF
Takeda Pharmaceutical Co Ltd. (TAK) has a current P/FCF of 8.24. The 5-year average P/FCF is 9.79. The thresholds are as follows: Strongly Undervalued below 3.92, Undervalued between 3.92 and 6.86, Fairly Valued between 12.73 and 6.86, Overvalued between 12.73 and 15.66, and Strongly Overvalued above 15.66. The current Forward P/FCF of 8.24 falls within the Historic Trend Line -Fairly Valued range.
Takeda Pharmaceutical Co Ltd (TAK) has a current Price-to-Book (P/B) ratio of 0.49. Compared to its 3-year average P/B ratio of 0.90 , the current P/B ratio is approximately -45.95% higher. Relative to its 5-year average P/B ratio of 0.97, the current P/B ratio is about -49.42% higher. Takeda Pharmaceutical Co Ltd (TAK) has a Forward Free Cash Flow (FCF) yield of approximately 14.50%. Compared to its 3-year average FCF yield of 11.60%, the current FCF yield is approximately 25.03% lower. Relative to its 5-year average FCF yield of 13.23% , the current FCF yield is about 9.61% lower.
0.49
P/B
Median3y
0.90
Median5y
0.97
14.50
FCF Yield
Median3y
11.60
Median5y
13.23
Competitors Valuation Multiple
The average P/S ratio for TAK's competitors is 869.99, providing a benchmark for relative valuation. Takeda Pharmaceutical Co Ltd Corp (TAK) exhibits a P/S ratio of 2208.25, which is 153.82% above the industry average. Given its robust revenue growth of -5.38%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TAK increased by 3.82% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 48.11 to 107.10.
The secondary factor is the Revenue Growth, contributed -5.38%to the performance.
Overall, the performance of TAK in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Takeda Pharmaceutical Co Ltd (TAK) currently overvalued or undervalued?
What is Takeda Pharmaceutical Co Ltd (TAK) fair value?
How does TAK's valuation metrics compare to the industry average?
What is the current P/B ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Nov 19 2025?
What is the current FCF Yield for Takeda Pharmaceutical Co Ltd (TAK) as of Nov 19 2025?
What is the current Forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Nov 19 2025?